Memantine Hydrochloride Milpharm

Memantine Hydrochloride, the active ingredient in Memantine Hydrochloride Milpharm, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients and works by modulating glutamatergic neurotransmission to reduce excitotoxic neuronal injury, helping to preserve cognitive function.

GNH USA supplies Memantine Hydrochloride Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers across global markets.

Memantine Hydrochloride is used in the management of neurodegenerative disorders that involve glutamatergic over‑activity, primarily Alzheimer’s disease.

Alzheimer’s disease: improves cognitive function and daily living activities in patients with moderate to severe disease.

Memantine Hydrochloride may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Seizures - Hypertension - Severe allergic reactions (e.g., rash, angioedema) - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing Memantine Hydrochloride, clinicians should consider several precautionary measures to ensure safe use.

- Renal function: assess and adjust dose in patients with impaired clearance. - Seizure history: monitor closely as the drug may lower seizure threshold. - Cardiovascular status: evaluate for hypertension or arrhythmias. - Hepatic impairment: use with caution and monitor liver enzymes. - Concomitant NMDA antagonists: avoid combined use to prevent additive effects. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Memantine Hydrochloride can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Amantadine: may reduce the therapeutic effect of memantine. - Ketamine: additive NMDA antagonism can increase neuropsychiatric side effects. - Other NMDA antagonists: combined use may lead to excessive inhibition.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Antihypertensive agents: monitor blood pressure for additive lowering. - Diuretics: watch for electrolyte disturbances that could affect neuronal stability.